Eurazeo SE (EPA:RF)

Oncternal Therapeutics Revenue

Eurazeo SE had revenue of -97.90M EUR in the half year ending December 31, 2024, a decrease of -102.87%. This brings the company's revenue in the last twelve months to -186.64M, down -155.24% year-over-year. In the year 2024, Eurazeo SE had annual revenue of 5.90M, down -98.54%.

• Revenue (ttm): -186.64M
• Revenue Growth: -155.24%
• P/S Ratio: -19.69
• Revenue / Employee: -339.97K
• Employees: 549
• Market Cap: 3.68B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	5.90M	-399.05M	-98.54%
Dec 31, 2023	404.95M	-5.24B	-92.83%
Dec 31, 2022	5.65B	-1.11B	-16.46%
Dec 31, 2021	6.76B	2.34B	52.96%
Dec 31, 2020	4.42B	-724.58M	-14.09%